Some pharmacological effects of delta-sleep-inducing peptide (DSIP).
The synthetic nonapeptide DSIP was studied in rabbits and cats under normal conditions and under conditions of disturbed sleep. In other experiments, the effect of the oligopeptide on withdrawal jumping provoked by naloxone in morphine-dependent mice was studied. In rabbits, DSIP at 25 micrograms X kg-1 i.v. and 1 mg X kg-1 s.c. augmented spindle-dominated, light nonREM sleep and prevented hyposomnia after a stressful situation. In cats, 25 micrograms X kg-1 i.v. and 100 micrograms X kg-1 s.c. preferentially augmented REM sleep and abolished the sleep suppressant effect of morphine. In morphine-dependent mice, 25.5 micrograms X kg-1 i.v. as well as doses beyond 85 micrograms X kg-1 s.c. attenuated naloxone-induced withdrawal jumping. In most experimental situations, indications for bell-shaped dose-response curves of DSIP were found.
D000818:Animals; D002415:Cats; D003701:Delta Sleep-Inducing Peptide; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D009020:Morphine / Q000009:adverse effects / Q000037:antagonists & inhibitors; D009270:Naloxone / Q000037:antagonists & inhibitors; D009842:Oligopeptides / Q000494:pharmacology*; D011817:Rabbits; D012890:Sleep / Q000187:drug effects*; D007319:Sleep Initiation and Maintenance Disorders / Q000517:prevention & control; D013315:Stress, Psychological / Q000150:complications; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D009842:Oligopeptides; D009270:Naloxone; D003701:Delta Sleep-Inducing Peptide; D009020:Morphine